ONCAlert | 2018 ASCO Annual Meeting

Genitourinary Cancers MORE >>

Olaparib in combination with abiraterone acetate improved progression-free survival compared with the antiandrogen agent alone in patients with metastatic castration-resistant prostate cancer, according to findings from a phase II trial presented at the 2018 ASCO Annual Meeting. The results of the trial were also published the same day in Lancet Oncology.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.